Scholarlink

Introduction <p>This retrospective database study investigated trends in insulin and use of concomitant noninsulin glucose-lowering medication (NIGLM) among Japanese individuals with diabetes.</p> Methods <p>The study comprised two analyses: (1) a serial cross-sectional analysis of patterns in insulin treatment by year (database: Real World Data); and (2) a longitudinal retrospective cohort analysis that examined insulin treatment and individuals’ characteristics (database: DeSC). Individuals initiating insulin in an inpatient or outpatient setting were followed up for 9&#xa0;months (type&#xa0;2 diabetes [T2D]) or 21&#xa0;months (type&#xa0;1 diabetes [T1D]) to evaluate treatment changes over time.</p> Results <p>The serial cross-sectional analysis included 4953 individuals (T2D, <i>n</i> = 4693; T1D, <i>n</i> = 260). The proportion of participants with T2D receiving concomitant NIGLMs increased from 31% in 2002 to 61% in 2021; from 2014 onwards, more than 30% of insulin-treated and basal-insulin-treated individuals treated with concomitant NIGLMs received dipeptidyl peptidase-4 inhibitors. Since 2018, use of concomitant NIGLMs in T1D has increased. The longitudinal retrospective cohort analysis included 27,492 individuals (T2D, <i>n</i> = 27,031; T1D, <i>n</i> = 461). Among participants with T2D who initiated insulin in an inpatient setting, 70.8% received bolus insulin at initiation, with this proportion declining to 17.3% after 9&#xa0;months; proportions of participants receiving basal insulin and of those receiving basal-bolus insulin increased over the same period (6.3–31.1% and 17.0–23.4%, respectively). The majority of participants with T2D who initiated insulin in an outpatient setting received basal insulin at initiation (hospital, 53.9%; clinic, 58.9%). Among participants with T1D who initiated insulin in an inpatient setting, 57.9% received bolus insulin, and basal-bolus insulin was the predominant regimen after 1&#xa0;month (85.0%); in outpatient settings, basal-bolus insulin was the predominant regimen throughout the study.</p> Conclusion <p>In Japan, the most prominent insulin regimen at initiation varied across settings in T2D but not in T1D; use of concomitant NIGLMs increased over time in both.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Retrospective Analysis of the Clinical Characteristics and Treatment Patterns Among Individuals with Diabetes Receiving Insulin Therapy in Japan: The Insulin JP2DB Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Michiaki Fukui,
  • Satoshi Tsuboi,
  • Yuiko Yamamoto,
  • Yasuo Terauchi

摘要

Introduction

This retrospective database study investigated trends in insulin and use of concomitant noninsulin glucose-lowering medication (NIGLM) among Japanese individuals with diabetes.

Methods

The study comprised two analyses: (1) a serial cross-sectional analysis of patterns in insulin treatment by year (database: Real World Data); and (2) a longitudinal retrospective cohort analysis that examined insulin treatment and individuals’ characteristics (database: DeSC). Individuals initiating insulin in an inpatient or outpatient setting were followed up for 9 months (type 2 diabetes [T2D]) or 21 months (type 1 diabetes [T1D]) to evaluate treatment changes over time.

Results

The serial cross-sectional analysis included 4953 individuals (T2D, n = 4693; T1D, n = 260). The proportion of participants with T2D receiving concomitant NIGLMs increased from 31% in 2002 to 61% in 2021; from 2014 onwards, more than 30% of insulin-treated and basal-insulin-treated individuals treated with concomitant NIGLMs received dipeptidyl peptidase-4 inhibitors. Since 2018, use of concomitant NIGLMs in T1D has increased. The longitudinal retrospective cohort analysis included 27,492 individuals (T2D, n = 27,031; T1D, n = 461). Among participants with T2D who initiated insulin in an inpatient setting, 70.8% received bolus insulin at initiation, with this proportion declining to 17.3% after 9 months; proportions of participants receiving basal insulin and of those receiving basal-bolus insulin increased over the same period (6.3–31.1% and 17.0–23.4%, respectively). The majority of participants with T2D who initiated insulin in an outpatient setting received basal insulin at initiation (hospital, 53.9%; clinic, 58.9%). Among participants with T1D who initiated insulin in an inpatient setting, 57.9% received bolus insulin, and basal-bolus insulin was the predominant regimen after 1 month (85.0%); in outpatient settings, basal-bolus insulin was the predominant regimen throughout the study.

Conclusion

In Japan, the most prominent insulin regimen at initiation varied across settings in T2D but not in T1D; use of concomitant NIGLMs increased over time in both.